ReviewAbdominal radiology (New York)2023
PI-RADS 3 lesions: a critical review and discussion of how to improve management.
Review in Abdominal radiology (New York), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The evolving PI-RADS paradigm.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- Development and external validation of a simple pre-biopsy risk stratification model for clinically significant prostate cancer in men with PI-RADS 3 lesions: a multicenter transperineal biopsy study.Frontiers in oncology · 2026Article
- AI in Prostate MRI: A Task-Based Review.Journal of the Korean Society of Radiology · 2025Review
- Combination of PI-RADS version 2.1 and amide proton transfer values for the detection of clinically significant prostate cancer.BMC cancer · 2025Article
- PSA proportion of index lesion: a novel index for predicting prostate pathology outcomes in biopsy-naïve patients with PSA < 10 ng/ml and PI-RADS 3 lesions.World journal of urology · 2025Article
- Performance of GPT-4 for automated prostate biopsy decision-making based on mpMRI: a multi-center evidence study.Military Medical Research · 2025Article
- Correlation of clinically significant prostate cancer sites across multiparametric MRI, prostate biopsy, and whole-mount pathology for optimal prostate biopsy strategy.Scientific reports · 2025Article
- Predictive impact of PI-RADS 3 lesion volume/total prostate volume ratio in prostate cancer diagnosis in biopsy-naïve patients.Turkish journal of medical sciences · 2025Article
- [Early detection of prostate cancer-individualized, risk-adapted and successful].Urologie (Heidelberg, Germany) · 2025Review
- The Added Value of Prostate Magnetic Resonance Imaging to Patient Selection.The Permanente journal · 2024Article
- [Prostate cancer screening-current overview].Radiologie (Heidelberg, Germany) · 2024Review
- Development of novel nomograms for predicting prostate cancer in biopsy-naive patients with PSA < 10 ng/ml and PI-RADS ≤ 3 lesions.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the publication of PI-RADS v1 in 2012, the debate regarding the question of how to manage PI-RADS 3 lesions has been mostly unsolved. However, based on our review of the current literature we discuss possible solutions and improvements to the original classification, factors such as PSAD (Prostate Specific Antigen Density), age, and tumor volume, in the decision of whether to proceed with a biopsy or not.
Indexed as
Identifiers
37160472What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.